Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Table 2 Univariate analyses for progression-free survival

Characteristics	No. (%)	Median PFS, month	HR (95% CI)	P value
Characteristics	(n = 88)	Median PFS, month	HR (95% CI)	P value
Age, years
≥ 75	26 (30)	10.0	1.96 (1.11–3.47)	0.020*
< 75	62 (70)	20.6	Reference	0.020*
Sex
female	14 (16)	17.5	1.02 (0.42–2.14)	0.955
male	74 (84)	18.4	Reference	0.955
Smoking status
smoker (current or former)	78 (89)	18.2	1.25 (0.57–3.29)	0.615
never smoker	10 (11)	18.4	Reference	0.615
ECOG PS
2–4	13 (15)	8.7	2.65 (1.24–5.17)	0.007*
0–1	75 (85)	19.6	Reference	0.007*
Histology
Squamous	24 (27)	15.2	1.17 (0.63–2.17)	0.624
Non-squamous	64 (73)	18.1	Reference	0.624
Stage
IV	67 (76)	17.7	1.19 (0.63–2.45)	0.605
IIIB	21 (24)	19.7	Reference	0.605
Pleural effusion or dissemination
present	21 (24)	18.5	0.88 (0.47–1.63)	0.685
absent	67 (76)	18.2	Reference	0.685
Bone metastasis
present	26 (30)	9.3	3.71 (2.04–6.73)	< 0.001*
absent	62 (70)	23.2	Reference	< 0.001*
Brain metastasis
present	11 (13)	19.6	0.93 (0.39–2.18)	0.858
absent	77 (88)	18.4	Reference	0.858
Adrenal grand metastasis
present	14 (16)	18.4	0.95 (0.44–2.02)	0.886
absent	74 (84)	18.2	Reference	0.886
Liver metastasis
present	14 (16)	19.6	0.78 (0.35–1.75)	0.543
absent	74 (84)	17.9	Reference	0.543
Number of metastatic organs
≥ 3	16 (18)	16.4	2.37 (1.20–4.41)	0.009*
< 3	72 (82)	20.6	Reference	0.009*
Early irAEs
present	41 (47)	17.5	1.05 (0.60–1.84)	0.857
absent	47 (53)	19.6	Reference	0.857

* P < 0.05
PFS progression-free survival, ECOG PS Eastern Cooperative Oncology Group performance status, irAE immune-related adverse event, HR hazard ratio, PFS progression-free survival

ISSN: 1471-2407